The end of Qutenza sends NGX-1998 into the neuropathic pain fray
This article was originally published in Scrip
Following the FDA's rejection of Qutenza (8% capsaicin patch) for the management of HIV-related pain, potential for the product in the future neuropathic pain market will remain limited to postherpetic neuralgia. NeurogesX will shift its focus to the development of NGX-1998 - a more user-friendly, liquid formulation of the drug. However, the shift towards an early pipeline product means that NeurogesX will have to face greater competition in the future neuropathic pain market as a number of agents are topical pipeline agents will provide fierce competition.